Health In Tech Inc. (NASDAQ: HIT), OSR Holdings Inc. (NASDAQ: OSRH), Theratechnologies Inc. (NASDAQ: THTX), and Leap Therapeutics Inc. (NASDAQ: LPTX) continue to push boundaries in healthcare through breakthroughs in insurtech, virtual access, immunotherapy, biologics, and precision oncology.
Health In Tech (NASDAQ: HIT) and DialCare to expand its self-funded health plans, providing nationwide virtual access to primary care, therapy, and psychiatry via its advanced eDIYBS platform. Health In Tech is a disruptive Insurtech platform company leveraging third-party AI technologies to streamline the healthcare insurance process through vertical integration, automation, and digital transformation. The company empowers TPAs, brokers, and carriers with tools that simplify underwriting, sales, and claims processing—ultimately driving efficiency in the self-funded healthcare space.
OSR Holdings' (NASDAQ: OSRH), subsidiary Vaximm AG announced successful Phase 2a results for its oral cancer vaccine VXM01 in combination with avelumab, demonstrating a strong safety profile and potential clinical benefit in recurrent glioblastoma patients.
Theratechnologies (NASDAQ: THTX), secured FDA approval for EGRIFTA WR™, a new formulation of tesamorelin to treat excess abdominal fat in adults with HIV and lipodystrophy. The once-weekly reconstitution improves patient convenience while maintaining bioequivalence.
Leap Therapeutics (NASDAQ: LPTX) reported positive Phase 2 data for sirexatamab (DKN-01), its anti-DKK1 antibody, in advanced colorectal cancer. Patients with high DKK1 levels or no prior anti-VEGF therapy showed significantly improved response rates and progression-free survival, supporting the potential for a registrational trial.
CS Diagnostics Corp. (OTCQB: CSDX) operates in the Medical Device & Biotechnology sector, specializing in radiation oncology solutions. The company focuses on advanced hydrogel technologies for cancer treatment, positioning itself within the broader healthcare and life sciences industry.
Together, these companies exemplify a dynamic convergence of tech-enabled care, targeted biologics, and breakthrough therapies aimed at improving patient outcomes across multiple fronts of the healthcare landscape.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.
Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com
